<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933383</url>
  </required_header>
  <id_info>
    <org_study_id>AQ-PRO-005</org_study_id>
    <nct_id>NCT04933383</nct_id>
  </id_info>
  <brief_title>Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics</brief_title>
  <acronym>BOREAS</acronym>
  <official_title>A Prospective, Active-controlled, Randomized, Open Label, Single-center, Multiple Dose, Crossover Clinical Trial to Assess the Efficacy, Safety and PK of AQ001S Compared to a Budesonide Inhalation Suspension in Adults With Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aquilon Pharmaceuticals S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquilon Pharmaceuticals S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, active-controlled, randomized, open label, single-center, multiple&#xD;
      dose, two-period crossover clinical trial to assess the efficacy, safety and pharmacokinetics&#xD;
      of AQ001S compared to a budesonide inhalation suspension (comparator) in adults with mild&#xD;
      asthma.&#xD;
&#xD;
      Both treatments will be administered by nebulization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults patients with mild asthma (18 to 65 years old), who are 'inhaled corticosteroid&#xD;
      (ICS)'-naïve for minimum 60 days at Screening Visit will be enrolled in the study. The&#xD;
      patients will be treated for 28 days. The primary endpoint will be assessed by a provocative&#xD;
      concentration of methacholine that results in a 20% drop (PC20) in the first second forced&#xD;
      expiratory volume (FEV1) as determined by methacholine challenge test. The pharmacokinetics&#xD;
      (PK) endpoint, i.e. PK profile of budesonide in plasma, and pharmacodynamics (PD) endpoints,&#xD;
      i.e. recording of symptom scores, use of reliever drugs as needed, biomarkers of airway&#xD;
      inflammation and pulmonary function tests will be assessed during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PC20 assessed by methacholine (MCh) challenge test</measure>
    <time_frame>At the end of Period 1 and end of Period 2 (each period is 29 days)</time_frame>
    <description>At Visit 1 (baseline), Visit 2 (28-day treatment period 1) and Visit 4 (28-day treatment period 2), a MCh challenge test will be performed, i.e. up to the administration of a concentration of MCh provoking an FEV1 fall of 20% (PC20). FEV1 is measured by spirometry. The change in PC20 from baseline to the end of each period (two periods) will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Over the treatment period, up to 29-day treatment period</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events as assessed by collection of (Serious) Adverse Events, general and local tolerability and hypothalamic-pituitary-adrenal (HPA) axis function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in FeNO measurements</measure>
    <time_frame>At the end of Period 1 and Period 2 (each period is 29 days)</time_frame>
    <description>Fractional exhaled nitric oxide (FeNO) measurements at Visit 1 (baseline), Visit 2 (treatment period 1) and Visit 4 (treatment period 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood eosinophil counts</measure>
    <time_frame>At the end of Period 1 and Period 2 (each period is 29 days)</time_frame>
    <description>Blood eosinophil counts at Visit 1 (baseline), Visit 2 (treatment period 1) and Visit 4 (treatment period 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma symptoms</measure>
    <time_frame>29-day treatment period</time_frame>
    <description>Day- and night-time of asthma symptoms over the treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose budesonide levels in plasma</measure>
    <time_frame>1-day treatment</time_frame>
    <description>Budesonide PK level in plasma measured at Visit 1 (baseline) and following the first single dose treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Budesonide levels in plasma</measure>
    <time_frame>At Day 28 of Period 1 and at Day 28 of Period 2</time_frame>
    <description>Budesonide PK level in plasma measured at Visit 2 (end of treatment period 1) and Visit 4 (end of treatment period 2). Blood samples will be performed at pre-dose and at 10, 20, 45, 120, 240 and 360 minutes after IMP administration (abridged PK).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>AQ001S 0.125 mg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AQ001S 0.125 mg/ml is a budesonide inhalation solution administered by nebulization once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>budesonide inhalation suspension 0.125 mg/ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonide 0.125 mg/ml is a budesonide inhalation suspension administered by nebulization once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQ001S 0.125 mg/ml</intervention_name>
    <description>administered by nebulization once daily</description>
    <arm_group_label>AQ001S 0.125 mg/ml</arm_group_label>
    <arm_group_label>budesonide inhalation suspension 0.125 mg/ml</arm_group_label>
    <other_name>budesonide inhalation solution 0.125 mg/ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 0.125 mg/ml inhalation suspension</intervention_name>
    <description>administered by nebulization once daily</description>
    <arm_group_label>AQ001S 0.125 mg/ml</arm_group_label>
    <arm_group_label>budesonide inhalation suspension 0.125 mg/ml</arm_group_label>
    <other_name>Budesonide inhalation suspension 0.125 mg/ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index between 18.5 and 29 kg/m2.&#xD;
&#xD;
          -  Documented clinical diagnosis of stable, persistent, asthma for at least 3 months&#xD;
&#xD;
          -  Subjects who are ICS-naïve for minimum 60 days at Screening Visit.&#xD;
&#xD;
          -  Positive methacholine (MCh) challenge test (concentration of MCh provoking an FEV1&#xD;
             fall of 20% [PC20] &lt; 8 mg/ml or dose of MCh provoking an FEV1 fall of 20% [PD20] &lt; 0.2&#xD;
             mg) in the last year.&#xD;
&#xD;
          -  Post-bronchodilator FEV1 at least 80% of the predicted, documented in the last year.&#xD;
&#xD;
          -  Clinical laboratory test results, 12-lead electrocardiogram (ECG), blood pressure and&#xD;
             heart rate (supine) within normal reference range or judged to be not clinically&#xD;
             significant by the Investigator.&#xD;
&#xD;
          -  Female subjects of childbearing potential should have a negative pregnancy test at&#xD;
             Screening Visit and use a highly effective method of contraception.&#xD;
&#xD;
          -  Reliable subjects who are willing to be available for the duration of the clinical&#xD;
             trial and willing to comply with clinical trial procedures.&#xD;
&#xD;
          -  Subjects who have the ability to understand the requirements of the clinical trial.&#xD;
&#xD;
          -  Subjects who have given written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current smokers or recent (&lt; 8 weeks) ex-smokers or ex-smokers if &gt; 10 pack-years.&#xD;
&#xD;
          -  Pregnant or breastfeeding female subjects.&#xD;
&#xD;
          -  Inability to carry out pulmonary function testing.&#xD;
&#xD;
          -  FEV1 &lt; 70%.&#xD;
&#xD;
          -  History of near-fatal asthma and/or intensive care unit admission for asthma symptoms.&#xD;
&#xD;
          -  Exacerbations of asthma requiring oral steroids, hospitalization or change in asthma&#xD;
             treatment in the previous three months.&#xD;
&#xD;
          -  Evidence of symptomatic chronic or acute respiratory infection in the previous 8&#xD;
             weeks.&#xD;
&#xD;
          -  Diagnosis of chronic obstructive pulmonary disease (COPD) or bronchiectasis.&#xD;
&#xD;
          -  Pulmonary malformations, tuberculosis, cystic fibrosis.&#xD;
&#xD;
          -  History of hypersensitivity or existing contraindication to budesonide or any other&#xD;
             Investigational Medicinal Product (IMP) ingredients.&#xD;
&#xD;
          -  Untreated oral candidiasis.&#xD;
&#xD;
          -  Immunosuppressive treatment, including systemic corticosteroids (e.g., oral,&#xD;
             parenteral, ocular, nasal), within 28 days before Screening Visit.&#xD;
&#xD;
          -  Use of ICS within 60 days before Screening Visit.&#xD;
&#xD;
          -  Use of anti-leukotrienes, immunoglobulins, beta-blockers, digitalis, amiodarone,&#xD;
             antifungals, macrolides, antidepressants, monoamine oxidase inhibitors, antiretroviral&#xD;
             drugs, cholinesterase inhibitors, histamine, theophylline, non-steroidal&#xD;
             anti-inflammatory drugs, anticholinergic drugs, neuroleptics, curariform drugs,&#xD;
             antihistaminic (anti-H1) drugs, calcium channel blockers, long acting&#xD;
             beta2-antagonists, mast cell stabilizers (e.g. natrium cromoglycate).&#xD;
&#xD;
          -  History of alcohol or drug abuse.&#xD;
&#xD;
          -  Unstable or life-threatening cardiac disease&#xD;
&#xD;
          -  History or presence of prolonged QT interval (&gt; 470 ms), or any other clinically&#xD;
             significant ECG abnormalities as judged by the Investigator based on 12-lead ECG&#xD;
             recordings at Screening Visit.&#xD;
&#xD;
          -  Diabetes mellitus.&#xD;
&#xD;
          -  Neuropsychiatric diseases.&#xD;
&#xD;
          -  Clinically relevant laboratory abnormalities at Screening Visit.&#xD;
&#xD;
          -  Blood or plasma donation within 30 days prior to Screening Visit.&#xD;
&#xD;
          -  History or presence of malignancy of any system organ class (other than localized&#xD;
             basal cell carcinoma of the skin), treated or untreated, within the past 5 years prior&#xD;
             to Screening Visit, regardless of whether there is evidence of local recurrence or&#xD;
             metastases.&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism, or excretion of drugs, or which may jeopardize the subject&#xD;
             in case of participation in the clinical trial.&#xD;
&#xD;
          -  History or presence of any other clinically relevant disease of any major system organ&#xD;
             class (e.g. cardiovascular, pulmonary, renal, hepatic, gastrointestinal, reproductive,&#xD;
             endocrinological, neurological, psychiatric or orthopedic disease) as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) and severe acute respiratory syndrome (SARS)-CoV-2&#xD;
             infections.&#xD;
&#xD;
          -  Subjects who participated in an investigational trial within the 12 weeks prior to the&#xD;
             start of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Benoît Martinot</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pneumocare SPRL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johan Silliard</last_name>
    <phone>+32495823443</phone>
    <email>johan.silliard@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pneumocare SPRL</name>
      <address>
        <city>Erpent</city>
        <state>Namur</state>
        <zip>5101</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Silliard</last_name>
      <phone>+32495823443</phone>
      <email>johan.silliard@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Jean-Benoît Martinot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

